Homepage > Company > Media > Pharma News > 2023 > Gilead Awarded $175.2 Million Over HIV Drug Fraud Scheme

Gilead Awarded $175.2 Million Over HIV Drug Fraud Scheme

A federal judge in Florida has awarded Gilead Sciences $175.2 million in damages over charges that the defendants fraudulently enrolled individuals in Gilead’s Medication Assistance Program then resold the company’s free PrEP HIV drugs Truvada (emtricitabine and tenofovir disoproxil fumarate) and Descovy (emtricitabine and tenofovir alafenamide).

The company filed its complaint in November 2020, seeking an injunction to halt the alleged “dangerous and fraudulent” schemes.

The judgment permanently blocks defendants Baikal Marketing Group, the Priority Health Medical Center and several individuals from enrolling or facilitating the enrollment of any individual in Gilead’s Patient Assistance Program, Medication Assistance Program or any program that provides access to free Gilead medication.

March 14, 2023

https://www.fdanews.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)